David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.

Chemotherapy is a preferred treatment option for patients with high-risk disease, Adelstein explains. Evidence suggests that the use of high-dose cisplatin benefits select patients in terms of locoregional control and survival. However, there is less evidence showing that weekly treatment with cisplatin is as effective.

No data suggest that carboplatin, cetuximab, or taxane-based therapies in the adjuvant setting have a role in these patients. Radiation therapy has also shown to be a reasonable approach in patients who are unable to tolerate cisplatin.

View more from the 2016 Multidisciplinary Head and Neck Cancer Symposium

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Multidisciplinary Head and Neck Cancer Symposium

David Adelstein, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses adjuvant therapy options for patients with oral cancer.


Dr. Adelstein on Adjuvant Therapy for Oral Cancer